KEGG   DRUG: Bimekizumab
Entry
D11550                      Drug                                   
Name
Bimekizumab (USAN/INN);
Bimekizumab (genetical recombination) (JAN);
Bimzelx (TN)
Formula
C6552H10132N1750O2029S42
Exact mass
147137.1715
Mol weight
147227.7921
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYNMAWVRQA PGKGLEWVAT ITYEGRNTYY
RDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCASPP QYYEGSIYRL WFAHWGQGTL
VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THTCPPCPAP
ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(Light chain)
AIQLTQSPSS LSASVGDRVT ITCRADESVR TLMHWYQQKP GKAPKLLIYL VSNSEIGVPD
RFSGSGSGTD FRLTISSLQP EDFATYYCQQ TWSDPWTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H152-H208, H228-L214, H234-H'234, H237-H'237, H269-H329, H375-H433, H'22-H'96, H'152-H'208, H'228-L'214, H'269-H'329, H'375-H'433, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AC21
Product: D11550<JP>
Efficacy
Antipsoriatic, Anti-IL-17A/IL-17F antibody
Comment
Monoclonal antibody
Treatment of moderate to severe plaque psoriasis
Target
IL17A [HSA:3605] [KO:K05489]
IL17F [HSA:112744] [KO:K05494]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04657  IL-17 signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC21 Bimekizumab
      D11550  Bimekizumab (USAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D11550  Bimekizumab (USAN/INN); Bimekizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11550  Bimekizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11550  Bimekizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL17A
     D11550  Bimekizumab (USAN/INN) <JP>
    IL17F
     D11550  Bimekizumab (USAN/INN) <JP>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11550
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11550
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11550
Other DBs
CAS: 1418205-77-2
PubChem: 384585526
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system